AZD2423

Cat. No.:	HY-135891
CAS No.:	1229603-37-5
Molecular Formula:	$C_{20}H_{29}ClFN_5O_2$
Molecular Weight:	425.93
Target:	CCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (234.78 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3478 mL	11.7390 mL	23.4780 mL
	5 mM	0.4696 mL	2.3478 mL	4.6956 mL
	10 mM	0.2348 mL	1.1739 mL	2.3478 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.87 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.87 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.87 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator. AZD2423 has an IC_{50} of 1.2 nM for CCR2 Ca^{2+} flux [1][2][3].

IC_{50} & Target

CCR2

In Vitro

AZD2423 inhibits MCP-1 induced calcium mobilization and chemotaxis of THP-1 cell line with an IC_{50} of 4 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. AZD2423.

[2]. John G. Cumming. CCR2 antagonists for the treatment of neuropathic pain: The discovery and development of AZD2423.

[3]. Kalliomäki J, et al. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain. 2013 May;154(5):761-7.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA